ondasdechoque.org
PT-BR

Plantar heel pain / plantar fasciopathy · Review · 2024

Does shockwave thin the plantar fascia and ease heel pain?

In this review of 14 trials, the plantar fascia became slightly thinner after shockwave than after other non-surgical treatments, by about 0.2 mm. Overall, pain fell about half a point more on a 0–10 scale, a difference that could be due to chance. Trials against steroid injections or sham favoured shockwave.

trials
14
adults with plantar fasciitis
867
months of follow-up
1–6

Good to know: Thickness is a scan measure; how people feel matters more. Very different comparison treatments were combined.

Simental-Mendía M, Simental-Mendía LE, Sánchez-García A, et al. Archives of Orthopaedic and Trauma Surgery, 2024 · Read the paper ↗

How this study worked

13 studiesOne answer
A review gathers earlier studies to answer one question.

What happened

studies
13
Compared with
Other non-surgical treatments, such as steroid injection, laser, stretching, insoles or sham

Heel pain compared with other treatments

Difference on a 0–10 pain scale · below zero means less pain with shockwave

Across 13 trials pain fell about 0.5 points more with shockwave, with a range that includes no difference. Against sham the gap was about 1.8 points, and against steroid injections about 1.3.
Show the numbers
Difference (points on a 0–10 pain scale)likely range
All comparisons (13 trials)−0.51−1.04 to 0.01
Versus sham−1.75−2.52 to −0.98
Versus steroid injection−1.26−1.86 to −0.66

What the trials used

Shockwave treatment in included trials
Focused and radial (including pneumatic ballistic) shockwaves were pooled together; regimens, energies and devices were not extracted or analysed. Seven of 14 trials added stretching exercises.
Thickness measurement
Mostly ultrasound at the calcaneal insertion; MRI in two trials; one trial measured 2 cm distal to the medial calcaneal tuberosity.

Who took part

867 adults with plantar fasciitis in 14 trials from 2012 to 2022; two trials included people with spondyloarthritis.

Side effects

The review does not report side effects.

All the numbers and the full appraisal
FROM THE FULL PAPER

The results, in numbers.

Adults with clinically or image-diagnosed plantar fasciitis in 14 parallel randomized trials published 2012–2022 (867 participants: 437 ESWT, 430 control), with fascia thickness measured by ultrasound or MRI and pain by VAS or NRS; two trials included people with spondyloarthritis. Follow-up 1 to 6 months.

Plantar fascia thickness1 reported outcome
01
End of follow-up, 1 to 6 months

Plantar fascia thickness

Plantar fascia thickness mm of plantar fascia thickness

WMD-0.21CI 95% -0.39 to -0.02p = 0.03

ESWT versus nonsurgical control treatments (pooled)

14 studies · 867 participants in this estimate · I²=63%; Tau²=0.06; Chi²=35.33, df=13, P=0.0008

Random-effects (DerSimonian–Laird), generic inverse variance, on pre–post change

-0.4Equal results 00

Fascia thickness fell more with ESWT than with the control treatments, by 0.21 mm on average (95% CI 0.02 to 0.39 mm). The authors note this is small against a typical thickness about 1 mm above normal.

Analysis details and source

Fragile: removing any one of four trials (Huo, Vahdatpour, Xu, Yilmez-Sanmak) moved P to 0.06–0.07, as the authors report (Results; Table 2). Figure 3 arm totals 437 ESWT and 430 control. Lee 2013 compared low- with medium-energy ESWT but is pooled as ESWT versus control.

Pain (VAS)1 reported outcome
02
End of follow-up, 1 to 6 months

Pain (VAS)

Pain (VAS) cm on a 0–10 cm VAS

WMD-0.51CI 95% -1.04 to 0.01p = 0.06

ESWT versus nonsurgical control treatments (pooled)

13 studies · I²=83%; Tau²=0.68; Chi²=71.41, df=12, P<0.00001

Random-effects (DerSimonian–Laird), generic inverse variance, on pre–post change

-1.2Equal results 00.1

Pain fell in both groups in most trials; the pooled extra reduction with ESWT, 0.51 cm, was not statistically significant (95% CI −1.04 to 0.01).

Analysis details and source

13 trials (one used NRS and was excluded); Figure 4 arm totals 398 and 392. Sensitive to single trials: removing Ulusoy, Tezel, Yilmez-Sanmak or Yan made the result significant (Table 3). Heterogeneity was high.

Thickness: ESWT versus corticosteroid injection1 reported outcome
03
End of follow-up, 1 to 6 months

Thickness: ESWT versus corticosteroid injection

Thickness: ESWT versus corticosteroid injection mm of plantar fascia thickness

WMD-0.28CI 95% -0.53 to -0.03p = 0.03

ESWT versus corticosteroid injection (subgroup)

Random-effects (DerSimonian–Laird), generic inverse variance, on pre–post change

-0.6Equal results 00.1

In trials comparing ESWT with steroid injection, thickness fell 0.28 mm more with ESWT.

Analysis details and source

Subgroup composition and heterogeneity are in an unread supplement; Table 1 lists four steroid-comparator trials.

Thickness: ESWT versus sham1 reported outcome
04
End of follow-up, 1 to 6 months

Thickness: ESWT versus sham

Thickness: ESWT versus sham mm of plantar fascia thickness

WMD-0.61CI 95% -1.19 to -0.02p = 0.04

ESWT versus sham ESWT (subgroup)

Random-effects (DerSimonian–Laird), generic inverse variance, on pre–post change

-1.3Equal results 00.1

Against sham, thickness fell 0.61 mm more with ESWT, with a wide interval.

Analysis details and source

Table 1 lists two sham-controlled trials (Caner 2022, Vahdatpour 2012); subgroup details are in the unread supplement.

Pain: ESWT versus corticosteroid injection1 reported outcome
05
End of follow-up, 1 to 6 months

Pain: ESWT versus corticosteroid injection

Pain: ESWT versus corticosteroid injection cm on a 0–10 cm VAS

WMD-1.26CI 95% -1.86 to -0.66p <0.0001

ESWT versus corticosteroid injection (subgroup)

Random-effects (DerSimonian–Laird), generic inverse variance, on pre–post change

-2.1Equal results 00.2

Against steroid injection, pain fell 1.26 cm more with ESWT; the authors say this exceeds a 0.8–0.9 cm minimal important difference for average pain but not 1.9 cm for pain.

Analysis details and source

Subgroup; composition and heterogeneity in the unread supplement.

Pain: ESWT versus sham1 reported outcome
06
End of follow-up, 1 to 6 months

Pain: ESWT versus sham

Pain: ESWT versus sham cm on a 0–10 cm VAS

WMD-1.75CI 95% -2.52 to -0.98p <0.0001

ESWT versus sham ESWT (subgroup)

Random-effects (DerSimonian–Laird), generic inverse variance, on pre–post change

-2.8Equal results 00.3

Against sham, pain fell 1.75 cm more with ESWT, again below the 1.9 cm threshold the authors cite.

Analysis details and source

Few trials; subgroup details in the unread supplement.

Thickness: trials with added stretching1 reported outcome
07
End of follow-up, 1 to 6 months

Thickness: trials with added stretching

Thickness: trials with added stretching mm of plantar fascia thickness

WMD-0.21CI 95% -0.58 to 0.17p = 0.28

ESWT versus control where stretching was added (subgroup)

Random-effects (DerSimonian–Laird), generic inverse variance, on pre–post change

-0.7Equal results 00.3

With stretching added, the thickness difference was not statistically significant.

Analysis details and source

Exact subgroup definition is in the unread supplement.

Pain: trials with added stretching1 reported outcome
08
End of follow-up, 1 to 6 months

Pain: trials with added stretching

Pain: trials with added stretching cm on a 0–10 cm VAS

WMD-0.46CI 95% -0.95 to 0.04p = 0.07

ESWT versus control where stretching was added (subgroup)

Random-effects (DerSimonian–Laird), generic inverse variance, on pre–post change

-1.1Equal results 00.2

With stretching added, the pain difference was not statistically significant.

Analysis details and source

The text prints this pain WMD in mm; the pain analyses otherwise use cm.

Effect by length of follow-up1 reported outcome
09
End of follow-up, 1 to 6 months

Effect by length of follow-up

Random-effects meta-regression Slope per month of follow-up

No association between follow-up length and the thickness (slope −0.014, 95% CI −0.167 to 0.137; P=0.848) or pain differences (slope −0.168, −0.809 to 0.472; P=0.607).

Analysis details and source

Methods describe follow-up duration; Results say "duration of treatment". Follow-up spanned only 1–6 months.

Publication bias checks1 reported outcome
10
End of follow-up, 1 to 6 months

Publication bias checks

Funnel plots, Egger and Begg tests, trim and fill P values

Funnel plots looked symmetric, trim and fill imputed no studies, and Egger (thickness P=0.234; pain P=0.406) and Begg tests (P=0.435; P=0.392) did not suggest small-study effects.

Analysis details and source

With 13–14 trials these tests have limited power.

How treatment was delivered
Shockwave treatment in included trials

Focused and radial (including pneumatic ballistic) shockwaves were pooled together; regimens, energies and devices were not extracted or analysed. Seven of 14 trials added stretching exercises.

Thickness measurement

Mostly ultrasound at the calcaneal insertion; MRI in two trials; one trial measured 2 cm distal to the medial calcaneal tuberosity.

HARMS & TOLERABILITY

Adverse events were not extracted or synthesized, so harms of ESWT relative to the control treatments are unknown from this review. Funding: no specific grant; conflicts of interest: none declared.

LIMITS OF THE ANALYSIS

Author-reported: radial and focused ESWT, regimens and devices were not distinguished; high heterogeneity; different control treatments; follow-up only short to medium term; sensitivity analyses suggest results are not robust.

Extractor interpretation: very different comparators (laser, prolotherapy, conditioned plasma, stretching, ultrasound, kinesiotaping, insoles, steroid injection, sham) were pooled, and Lee 2013, a low- versus medium-energy ESWT comparison, entered as ESWT versus control.

Robustness and inconsistencies: the authors report that removing any of four trials (Xu, Yilmez-Sanmak, Huo, Vahdatpour) makes the thickness result non-significant (Table 2). The Discussion says all trials reported thinner fascia, but Figure 3 shows Lai 2018 at +0.1 mm in both arms; the stretching pain WMD is printed in mm.

Risk of bias (RoB 2): overall low in one trial (Hocaoglu 2017), some concerns in 13; no trial rated high. Seven trials were unblinded, six single-blinded and one double-blinded. No certainty-of-evidence (GRADE) rating. Some SDs were derived from SE or t statistics, and medians were converted to means.

Findings checked against the full source by a separate automated reviewer.

Limitations noted by the reviewers

  • Author-reported: radial and focused ESWT, regimens and devices were not distinguished; high heterogeneity; different control treatments; follow-up only short to medium term; sensitivity analyses suggest results are not robust.
  • Extractor interpretation: very different comparators (laser, prolotherapy, conditioned plasma, stretching, ultrasound, kinesiotaping, insoles, steroid injection, sham) were pooled, and Lee 2013, a low- versus medium-energy ESWT comparison, entered as ESWT versus control.
  • Robustness and inconsistencies: the authors report that removing any of four trials (Xu, Yilmez-Sanmak, Huo, Vahdatpour) makes the thickness result non-significant (Table 2). The Discussion says all trials reported thinner fascia, but Figure 3 shows Lai 2018 at +0.1 mm in both arms; the stretching pain WMD is printed in mm.
  • Risk of bias (RoB 2): overall low in one trial (Hocaoglu 2017), some concerns in 13; no trial rated high. Seven trials were unblinded, six single-blinded and one double-blinded. No certainty-of-evidence (GRADE) rating. Some SDs were derived from SE or t statistics, and medians were converted to means.
Research review

Source-linked critical reading

Systematic review and meta-analysis of randomized trials

Reading depthMaterial consulted
Technical source record

Full local PDF read: all 14 pages including rotated Table 1 from page images, Tables 2–3, Figures 1–6, Methods, Results, Discussion, funding, declarations and references. Online Supplementary Tables 1–4 were not available and were not read.

Review statusAI-assisted draft · independent automated checkThis automated check comes before the editor’s clinical review.
Study design

PROSPERO-registered (CRD42021243774) systematic review and random-effects meta-analysis following PRISMA. MEDLINE, Embase, Web of Science and Scopus to June 2022 plus ClinicalTrials.gov, no language limit; duplicate screening and extraction; RoB 2; leave-one-out, subgroup, meta-regression and publication-bias analyses.

Participants and setting

Adults with clinically or image-diagnosed plantar fasciitis in 14 parallel randomized trials published 2012–2022 (867 participants: 437 ESWT, 430 control), with fascia thickness measured by ultrasound or MRI and pain by VAS or NRS; two trials included people with spondyloarthritis. Follow-up 1 to 6 months.

Treatment

Any ESWT, focused or radial, with regimens and devices not analysed; seven trials added stretching exercises.

Comparison

Nonsurgical controls pooled together: low-level laser, prolotherapy, autologous conditioned plasma, stretching, ultrasound, kinesiotaping, orthopaedic insoles, corticosteroid injection and sham ESWT; one trial compared two ESWT energy levels.

Outcomes and timing

Change in plantar fascia thickness (mm) and in pain (0–10 cm VAS) from baseline to the end of follow-up, 1 to 6 months, compared between groups as weighted mean differences.

What the results show

Thickness fell slightly more with ESWT: WMD −0.21 mm (95% CI −0.39 to −0.02; 14 trials, 867 participants; I²=63%), a result that lost significance when any of four trials was removed. Pain did not differ significantly: WMD −0.51 cm (−1.04 to 0.01; 13 trials; I²=83%). Subgroups favoured ESWT over steroid injection (thickness −0.28 mm; pain −1.26 cm) and sham (−0.61 mm; −1.75 cm).

Harms

Adverse events were not extracted or synthesized, so harms of ESWT relative to the control treatments are unknown from this review. Funding: no specific grant; conflicts of interest: none declared.

Limits and disclosures

Very different comparators were pooled, including one ESWT-versus-ESWT trial; radial and focused treatment were not separated; heterogeneity was high and results were sensitive to single trials. The Discussion’s statement that every trial showed thinning conflicts with Figure 3 (Lai 2018), subgroup details are only in an unread supplement, there is no GRADE rating, and follow-up ends at 6 months. No specific funding; no conflicts declared.

Application to care

Applies to short-term (1–6 month) results in adults with plantar fasciitis. Fascia thickness is an imaging marker; this review does not show that the small thickness change matters to patients, and it gives no guidance on device type, energy or number of sessions.

What remains to be tested

Separate analyses by comparator and by radial versus focused ESWT, harms data, certainty ratings, and trials with blinded thickness measurement and follow-up beyond 6 months linking thickness change to pain and function.

THE ORIGINAL SOURCE

Read the original article.

Effect of extracorporeal shockwave therapy on plantar fascia thickness in plantar fasciitis: a systematic review and meta-analysis of randomized controlled trials.

Simental-Mendía M, Simental-Mendía LE, Sánchez-García A, Sahebkar A, Jamialahmadi T, Vilchez-Cavazos F, Peña-Martínez VM, Acosta-Olivo C. · Archives of orthopaedic and trauma surgery · 2024

Open the publication record or available full-text files.

Checked against the full paper · Clinical review: Dr. Marcus Yu Bin Pai, · How we review →